Clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer
| Project/Area Number |
15K10153
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kindai University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
杉浦 史哲 近畿大学, 医学部附属病院, 講師 (10580631)
奥野 清隆 近畿大学, 医学部, 教授 (30169239)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 大腸癌 / ペプチドワクチン / 術後補助療法 / CTL反応 / 細胞障害性T細胞 / 細胞障害性Tリンパ球 / CTL |
|---|
| Outline of Final Research Achievements |
We conducted a phase II clinical trial involving patients with stage III CRC. All enrolled patients whose human leukocyte antigen (HLA)-A status was double-blinded were administered the same regime of a peptide vaccine and UFT/LV chemotherapy. The primary objective of the study was the comparison of relapse-free survival (RFS) in patients with HLA-A*2402 versus those without HLA-A*2402. A total of 46 patients were enrolled in the study. Three-year RFS was not significantly different between HLA-A*2402 matched and unmatched groups. Three-year RFS was significantly better in patients with positive CTL responses in the HLA-A*2402 matched group compared with those without. In conclusion, vaccination-induced immune responses combined with UFT/LV are positively associated with survival benefit in patients with HLA-A* 2402-positive stage III CRC.
|
Report
(4 results)
Research Products
(13 results)
-
-
-
[Journal Article] MicroRNA-6826 and -6875 in plasma are valuable non invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer.2017
Author(s)
Kijima T, Hazama S, Tsunedomi R, Tanaka H, Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K, Suzuki N, Takeda S, Ueno T, Yamamoto S, Yoshino S, Okuno K, Nagano H.
-
Journal Title
Oncology Reports
Volume: 37
Issue: 1
Pages: 23-30
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
